Prescribing information

 

Inclisiran is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:

  • in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
  • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.1

We appreciate your time is precious and it is difficult to fit things in around your busy working day – that’s why we have created this events and webinars page where you can connect with the latest evidence and opinions on cholesterol management in your own time.

If you would like to hear about upcoming events, you can sign up to receive our email communications.

Watch webinars on-demand

Below you can access recordings from educational webinars hosted by experts in the field of ASCVD and organised by Novartis. As the site grows, we’ll be adding lots of new content, so keep checking back.

 

'Overcoming lipid challenges in patients with multiple comorbidities' webinar title screen.

Introducing an innovative approach to lipid management with inclisiran▼ (Leqvio®)
A recording of a Novartis-organised webinar on 1st July 2021.

Watch Dr Tracey Vell MBE, Dr Jaimini Cegla, and Dr Matt Kearney talk about why lipid management is one of NHS England’s priority areas, the challenges currently faced in managing lipids in primary care and the potential role of inclisiran.

Watch now

 

 

 

 

Overcoming lipid challenges in patients with multiple comorbidities
A recording of the Novartis symposium on 23rd April 2021 at The Diabetes UK Professional Conference 2021.

Watch Dr Yassir Javaid, GPwSI in Cardiology, and Dr Ameet Bakhai, Consultant Cardiologist and Research Director, discuss the lipid management in complex patients with multiple comorbidities, and how a novel treatment may help overcome the associated challenges.

 

 

 

 

Inclisiran▼ (Leqvio®): Overcoming challenges in patients with uncontrolled LDL-C
A recording of the Novartis symposium on 9th June at The British Cardiovascular Society (BCS) Annual Conference 2021.

Watch Professor Kausik K. Ray, Professor of Public Health and Honorary Consultant Cardiologist, and Dr Derek Connolly, Consultant Interventional Cardiologist, discuss the current unmet needs in dyslipidaemia management, and provide an overview of inclisiran’s clinical trial data and innovative mechanism of action.

 

 

 

LDL cholesterol management: What more can be done? The role of Inclisiran▼ (Leqvio®)
A recording of the Novartis symposium on 10th June at MIMS Learning Live Digital 2021.

Watch Professor Kausik K. Ray, Professor of Public Health and Honorary Consultant Cardiologist, and Professor Terry McCormack, Vice-President of the British and Irish Hypertension Society and Honorary Professor of Cardiovascular Medicine, discuss the current unmet needs in lipid control and the role that inclisiran and primary care can play in helping to tackle the burden of ASCVD.

 

Inclisiran is not yet available to prescribe in the UK.

 

ASCVD, atherosclerotic cardiovascular disease; GPwSI, general practitioner with special interest; LDL-C, low-density lipoprotein cholesterol

References

  1. Leqvio® Summary of Product Characteristics.
Rate this content: 
No votes yet
UK | July 2021 | 133219
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]